Winning KERX Stock Forecast: Keryx Biopharmaceuticals Continues To Save Its Patients And Surges With 19.55% In 7 Days

“Revenue growth in the first quarter of 2018, as compared to the first quarter of 2017, was driven by an increase in Auryxia prescription and tablet demand, partially offset, by a reduction in the net price realized per tablet due to an increase in our gross-to-net adjustment”

– Scott Holmes, Senior Vice President and CFO of Keryx Biopharmaceuticals

[Image Source: Glassdoor]

Over the 7 days period from May 9th to May 16th, 2018 KERX stock price saw significant price jump of more than 19%. The overall KERX stock performance indicators for the last quarter suggest that this may be the consequence of the company’s results achieved in 1Q 2018. Based on the press release on May 10, 2018 the following highlights are important to analyse:

  • First quarter 2018 total revenues of $21.7 million, including net U.S. Auryxia® (ferric citrate) product sales of $20.6 million; a 96 percent increase compared to the first quarter of 2017
  • Approximately 34,600 Auryxia prescriptions were reported in the first quarter of 2018, representing 6.9 million Auryxia tablets. This compares to approximately 15,800 prescriptions and 3.4 million Auryxia tablets in the first quarter of 2017
  • The company exchanged its $125 million convertible senior notes due 2020 issued in 2015 and raised an additional $10 million in a private transaction with funds managed by The Baupost Group L.L.C.

The above highlights could not pass unseen by the market and investors observed KERX stock growth of 19.55% during the above-mentioned period. The below chart illustrates this:

At the same time, the analyst community mostly took hold positions on KERX stock over the last 4 months and indicating the average expected price of $6.64 being 27% more than the actual KERX stock price:

[Source: Yahoo Finance]

On May 9, 2018, I Know First issued a bullish 7 days forecast for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). The forecast illustrated a signal of 7.18 and a predictability of 0.16. In accordance with the forecast, KERX stock returned 19.55% over this period, highlighting the accuracy of the prediction produced by the I Know First algorithm.

Current I Know First subscribers received this bullish KERX forecast on May 9, 2018.

To subscribe today click here.

Best Pharma Stocks

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.


Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.